Last updated May 9, 2017
A board of directors, accountable to the members of the company (the Medical Research Council and The Wellcome Trust), act as company directors and as charity trustees. They have overall responsibility for the direction, management and control of UK Biobank Limited. The Board is chaired by Sir Mike Rawlins.
Sir Michael Rawlins
Professor Martin Bobrow
Professor Ruth Gilbert
Professor Andrew Hattersley
Dr Sara Marshall, Wellcome Trust
Dr Joe McNamara, MRC
Professor Bill Ollier
Mr Jonathan Tross CB
Mr Patrick Vallance
Sir Alex Markham
Mr Jonathan Sellors is Board Secretary.
Professor Sir Michael Rawlins
Sir Michael Rawlins has been chairman of the National Institute of Health & Clinical Excellence (NICE) since its formation in 1999. He is president-elect of the Royal Society of Medicine and assumes office in July 2012. He is also an Honorary Professor at the London School of Hygiene and Tropical Medicine, University of London, and Emeritus Professor at the University of Newcastle upon Tyne. He was the Ruth and Lionel Jacobson Professor of Clinical Pharmacology at the University of Newcastle upon Tyne from 1973 to 2006 .At the same time he held the position of consultant physician and consultant clinical pharmacologist to the Newcastle Hospitals NHS Trust. He was vice-chairman (1987-1992) and chairman (1993-1998) of the Committee on Safety of Medicines; and chairman of the Advisory Council on the Misuse of Drugs (1998 – 2008).
Andrew Hattersley is Professor of Molecular Medicine at the University of Exeter Medical School. He is a leading clinical scientist, who is distinguished for his contributions to the understanding of the genetics of diabetes and the application of that knowledge to clinical practice. He set up and currently heads the premier international research team working on monogenic diabetes and played a leading role in the genetics of type 2 diabetes. He continues to work as a consultant physician in diabetes while at the same time leading a large research team. Andrew Hattersley qualified from Oxford in 1984. He trained in Diabetes at the Hammersmith Hospital, Oxford and Birmingham before taking up his present post as a consultant diabetologist in Exeter in 1995. He was elected a fellow of The Royal Society in July 2010.
Dr Sara Marshall
Sara Marshall joined the Wellcome Trust in January 2016.She obtained her medical degree from the National University of Ireland, and worked as a junior doctor in Dublin before going to Stanford University, California as fellow in Lung Transplantation. She completed her training in clinical immunology in 1998, and has a PhD from the University of Cambridge on Immune Tolerance. She held an MRC Clinician Scientist award at the University of Oxford, and was then a Clinical Senior Lecturer in Imperial College where her research interests focussed on the genetics of transplantation and inflammatory diseases. Prior to joining the Trust, she was Professor of Clinical Immunology at the University of Dundee, where she was also Director of the Dundee Clinical Academic Track and Deputy Head of R&D for NHS Tayside.
Bill Ollier is Professor of Immunogenetics at Manchester University and Co-Director of the Centre for Integrated Genomic Medical Research. He also currently holds the position of Director of Research and Development with Salford Royal Foundation NHS Trust and NHS Salford. He graduated with a BSc in Zoology from the University College of Wales, Aberystwyth in 1973 and was awarded a PhD from the University of London in 1980 for his research into renal transplant rejection. He moved to the University of Manchester in 1988 to set up genetic epidemiology laboratories within the internationally renowned Arthritis Research Campaign’s Epidemiology Research Unit. He was Chairman of the British Society for Histocompatibility and Immunogenetics between 1994 to 1999. Professor Ollier’s research interests are focused largely on investigating the genetic basis of common complex disorders. These have centred primarily on rheumatic diseases, inflammatory and autoimmune conditions, neurocognitive disorders, and complex traits in companion animals. More recently he has developed an interest in pharmacogenetics and research into variability in efficacy and the development of adverse reactions to anti-inflammatory agents and new biological therapies. He has a long standing interest and expertise in the area of biobanking and sample management. He was a founder board member of the international biobanking initiative, Public Population Projects in Genomics ( P3G). The UK DNA Banking Network, a major national resource of samples and data, is held in his Department.
Mr Jonathan Tross CB
Jonathan Tross is Non Executive Director since June 2013 and Chair of the Audit and Risk Committee from October 2013. He is also currently a Non Executive Director at the National Institute for Health and Care Excellence (NICE) and a non executive Commissioner at the Independent Police Complaints Commission (IPCC). In both organisations he chairs the Audit and Risk Committee. Jonathan is a former senior civil servant with considerable experience in delivering public services and social policy, particularly in the fields of health, social security, child protection and the rights of individuals. Since leaving the civil service he has worked for the Local Government Association, was a Trustee for six years at Citizens Advice (the national body for the citizens advice movement) and has been an external case reviewer for the Parliamentary and Health Service Ombudsman.
Patrick is President, Pharma R&D and a member of the GSK Corporate Executive Team. He is responsible for the pharmaceutical pipeline: leading delivery of current late stage portfolio, and ensuring sustainability of R&D productivity through innovation. Patrick joined GSK in May 2006 as Head of Drug Discovery. He transformed GSK’s discovery engine by driving a more entrepreneurial culture. Patrick established the Discovery Investment Board, and by focused small, empowered teams, Discovery Performance Units, on therapy areas with the most promising science. Between June 2010 and December 2011, Patrick integrated discovery and development into Therapy Area Units to sharpen the focus on pipeline delivery and execution. Prior to joining GSK, Patrick was a clinical academic and led the Division of Medicine at UCL. He has over 20 years’ experience of clinical medicine, general internal medicine, cardiovascular medicine and clinical pharmacology. He was elected to the Academy of Medical Sciences in 1999 and subsequently became its Registrar before leaving to join GSK.